Hangaeur et al. found that pretreatment of HER2-amplified breast cancer line BT474 parental cells with the GPX4 inhibitor RSL3 reduces the amount of persister cells that remain after subsequent treatment with the HER2 inhibitor lapatinib, suggesting that GPX4-sensitive cells pre-exist [40]. Here, ERBB2 is linked to breast cancer.